MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, Fu P, Huang H, Bagai R, Jiang S, Kresak A, Howell S, Vasanji A, Flask CA, Halmos B, Koon H, Ma PC.
Fan W, et al.
Cancer Res. 2011 Jul 1;71(13):4494-505. doi: 10.1158/0008-5472.CAN-10-2668. Epub 2011 May 9.
Cancer Res. 2011.
PMID: 21555370
Free PMC article.